Variables | Tofacitinib 5 mg BID, N = 98 | Tofacitinib 10 mg BID, N = 99 | ADA 40 mg SC Q2W, N = 95 |
---|---|---|---|
mTSS nonprogression (change ≤ 0.5), n (%) | 94 (95.9) | 94 (94.9) | 93 (97.9) |
mTSS nonprogression (change ≤ 0), n (%) | 89 (90.8) | 92 (92.9) | 91 (95.8) |
mTSS nonprogression (SDC, change ≤ 0.66), n (%) | 94 (95.9) | 94 (94.9) | 93 (97.9) |
LSM change from BL mTSS (SE) | 0.01 (0.067) | −0.01 (0.067) | −0.07 (0.069) |
LSM change from BL erosion score (SE) | 0.02 (0.059) | −0.00 (0.059) | −0.06 (0.062) |
LSM change from BL JSN score (SE) | −0.01 (0.021) | −0.01 (0.021) | −0.01 (0.021) |
↵* Linear extrapolation applied at Month 12. No. patients with imputed values at Month 12 by linear extrapolation: tofacitinib 5 mg BID (n = 3); tofacitinib 10 mg BID (n = 4); adalimumab (n = 3). LSM were based on an ANCOVA model. ADA: adalimumab; BID: twice daily; BL: baseline; JSN: joint space narrowing; LSM: least squares mean; mTSS: modified Total Sharp Score; N: no. patients with data available at Month 12 after linear extrapolation; n: no. patients with nonprogression; Q2W: once every 2 weeks; SC: subcutaneous; SDC: smallest detectable change; SE: standard error.